$1.26B in CY2024 Part D spend699K claims · 508K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Denosumab used for?
Stoboclo is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at hi....
Is there a generic for Denosumab?
No. Denosumab is brand-only with no generic equivalents currently in market.
How much does my plan pay for Denosumab?
Across 329 Part D plans, Denosumab averages $1853.35/unit (NADAC). Lowest available: $1535.81/unit. Highest in distribution: $2001.52/unit.
Is Denosumab on the FDA shortage list?
No. Denosumab is not currently on the FDA Drug Shortage Database.
6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (5 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.